Navigator Medicines files Form D for $40 million offering
The Delaware biotechnology company registered a new exempt securities notice with the SEC, reporting $10 million already raised from three investors.
Navigator Medicines, Inc., a Delaware corporation incorporated within the last five years, in 20241, filed a Form D notice with the Securities and Exchange Commission. The filing lists the company's principal place of business at 1825 S Grant St., Suite 200, San Mateo, California 944021.
The notice classifies Navigator Medicines under the biotechnology industry group within health care1. The company claimed exemption under Rule 506(b)1 and reported a date of first sale of 2026-09-181, with the issuer indicating it intends the offering to last more than one year1.
According to the filing, the total offering amount is $40,000,000, with $10,000,000 already sold and $30,000,000 remaining to be sold1. The company reported that three investors have already invested in the offering1. No sales commissions or finder's fees were reported, as the filing states sales commissions and finders' fees were both listed as $01.
The Form D names several related persons. Tausif Butt and Stephen Basil Thomas are both listed with relationships as Executive Officer, Director, and Promoter1. Scott Forrest is listed only with the relationship of Executive Officer1, without director or promoter designations. Wouter Joustra, Khurem Farooq, and Mathias Vinther are each listed as Director1 only, while Kristie Grebe is listed as Executive Officer1 only.
The filing was signed by Tausif Butt, Chief Executive Officer, on 2026-09-251.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.